Primary Sclerosing Cholangitis Market is expected to Hit US$ 987.26 million by 2033 | Major Companies - Chemomab Therapeutics Ltd., Mirum Pharmaceuticals, Inc., Ipsen S.A., Gilead Sciences, Inc.

DataM Intelligence has unveiled its latest report on the "Primary Sclerosing Cholangitis Market Size 2026" delivering powerful insights into key trends, future growth opportunities, and evolving market challenges. Designed to empower smarter decision-making, the report equips businesses with the strategic intelligence needed to stay ahead in a competitive landscape. By blending robust qualitative analysis with data-driven quantitative research, DataM Intelligence offers a well-rounded perspective that helps organizations decode complex market dynamics, unlock new avenues for growth, and seize emerging opportunities in an ever-evolving global market.

Download Free Sample Report (Get Higher Priority for Corporate Email ID): https://datamintelligence.com/download-sample/primary-sclerosing-cholangitis-market?sz

The Global Primary Sclerosing Cholangitis Market size reached US$ 385.67 million in 2025 and is expected to reach US$ 987.26 million by 2033, growing with a CAGR of 12.21 % during the forecast period 2026-2033.

The Primary Sclerosing Cholangitis Market encompasses the development, production, and commercialization of therapies, diagnostics, and supportive care for PSC, a chronic liver disease characterized by inflammation and scarring of the bile ducts. The market includes pharmaceutical treatments, biologics, and emerging therapies aimed at slowing disease progression, managing symptoms, and preventing complications such as liver failure or cholangiocarcinoma. Growth is driven by rising disease prevalence, increasing awareness, advancements in targeted therapies, and expanding diagnostic capabilities globally, addressing an unmet medical need in hepatology.

Unlock Strategic Partnerships in the Growing Primary Sclerosing Cholangitis Market-Connect with Key Industry Leaders Today: https://www.datamintelligence.com/partner-identification-enquiry/primary-sclerosing-cholangitis-market?sz

Recent Industry Developments: United States

✅ March 2026: Transplant and post‐transplant care expansion: Analyst commentaries in early 2026 pointed to rising liver transplant volumes and expanded post‐transplant management programs as a key demand driver for PSC‐related diagnostics, monitoring tools, and supportive therapies in the U.S., reinforcing the growth trajectory of the specialty‐liver‐care segment.

✅ February 2026: Biologics and orphan‐incentive momentum: Industry outlooks in early 2026 noted that biologic‐based assets and orphan‐drug‐designated programs are accelerating the U.S. PSC R&D pipeline, with several companies obtaining regulatory designations and advancing Phase 2/3 trials, which is projected to increase both patient access and pricing intensity in the U.S. market.

✅ January 2026: Pipeline‐driven growth emphasis: Market‐forecasts published in early 2026 highlighted that the U.S. PSC market is expected to grow at a notable compound annual rate through 2034, driven by several emerging therapies such as volixibat, elafibranor‐based regimens, and CM‐101 (nebokitug), positioning the U.S. as the largest regional share in the seven‐major‐markets (7MM) landscape.

Recent Industry Developments: Japan

✅ March 2026: Asian‐specific epidemiology shaping diagnostics: Recent multi‐center Asian studies cited in early 2026 emphasized distinct PSC-IBD patterns in Japanese and broader Asian cohorts, prompting local diagnostic and monitoring strategies to adapt, which in turn is fueling demand for Japan‐specific algorithms and imaging‐based early‐detection tools.

✅ February 2026: Precision‐medicine and biologics adoption: Analyses in early 2026 highlighted that Japan's PSC market is gradually shifting toward personalized‐medicine approaches, including biologics and advanced immunotherapies, supported by national healthcare‐reimbursement reforms and academic-industry collaborations that are expanding the treatment armamentarium beyond standard care.

✅ January 2026: Growth‐forecast revision upward: A Japan‐focused PSC market report released in early 2026 projected that the domestic PSC market will expand at a high single‐digit compound annual growth rate through the early 2030s, reflecting increasing diagnosed prevalence, improved imaging‐based detection (e.g., MRCP), and a growing tariff base for novel therapies.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/primary-sclerosing-cholangitis-market?sz

List of the Key Players in the Primary Sclerosing Cholangitis Market:

Chemomab Therapeutics Ltd.
Mirum Pharmaceuticals, Inc.
Ipsen S.A.
GENFIT
Gilead Sciences, Inc.
Pliant Therapeutics, Inc.
Immunic, Inc.
Dr. Falk Pharma GmbH
SCOHIA PHARMA, Inc.
Sirnaomics Ltd.

How Does Market Research Work in the Primary Sclerosing Cholangitis Market?

Market research for the Primary Sclerosing Cholangitis Market involves systematic data collection and analysis to understand industry trends, customer behavior, and competitive dynamics. It includes primary research such as surveys and interviews, and secondary research from reports, databases, and publications. Analysts evaluate market size, growth drivers, challenges, and opportunities using qualitative and quantitative methods. Insights are validated through expert opinions and forecasting models, enabling businesses to make strategic decisions, identify target segments, and gain a competitive advantage in a rapidly evolving market.

Latest Mergers and Acquisitions of Primary Sclerosing Cholangitis Market:

✅ In April 2026: Esperion Therapeutics closes acquisition of Corstasis Therapeutics
Esperion completed its acquisition of Corstasis, bringing the FDA‐approved nasal diuretic EnbumystTM into its portfolio. While this is primarily a cardiovascular/edema play, the expanded hepatic and renal disease exposure strengthens Esperion's broader rare disease position, which also includes PSC development initiatives and pipeline expansion in metabolic/hepatic areas.

✅ In April 2026: Athyrium Capital Management and Esperion strategic financing to support the Corstasis acquisition
Athyrium entered a $50 million royalty financing to back Esperion's Corstasis acquisition, reinforcing the strategic deal's financial underpinnings. Although not a classic merger/acquisition itself, it is tied directly to this M&A and supports expanded operations that include PSC‐related research areas.

✅ January 2026: Mirum Pharmaceuticals completes acquisition of Bluejay Therapeutics
Mirum Pharmaceuticals finalized its acquisition of Bluejay Therapeutics, adding the late‐stage brelovitug program to its rare liver disease portfolio. Mirum's pipeline includes volixibat in late‐stage development for PSC, so this deal expands its rare liver focus and indirectly supports PSC‐related R&D.

Segments Covered in the Primary Sclerosing Cholangitis Market 2026:

By Treatment: Medication-based Therapies, Bile Duct Blockages, Liver Transplantation.

By Disease Stage: Early-stage PSC, Moderate-stage PSC, Advanced-stage PSC.

By Patient Age: Child (0-18), Adult (18 and above).

By End-User: Hospitals, Specialty Clinics, Others.

Regional Analysis of the Primary Sclerosing Cholangitis Market:

⇥ North America: Leads the market due to advanced infrastructure, strong R&D investments, and early adoption of new technologies.

⇥ Europe: Shows steady growth supported by strict regulations and increasing focus on sustainability initiatives.

⇥ Asia-Pacific: Fastest-growing region driven by rapid industrialization, urbanization, and rising consumer demand in emerging economies.

⇥ Latin America: Experiences moderate growth with expansion in industrial and commercial sectors.

⇥ Middle East & Africa: Gradual market growth supported by increasing investments and improving economic conditions.

Looking For Full Report? Get it Here: https://www.datamintelligence.com/buy-now-page?report=primary-sclerosing-cholangitis-market

Key Benefits of the Report:

⏩ Comprehensive Market Insights: Gain a deep understanding of market size, trends, and structure.

⏩ Accurate Forecasting: Access reliable future projections to support long-term planning.

⏩ Competitive Analysis: Identify key players, strategies, and positioning in the market.

⏩ Data-Driven Decisions: Make informed business choices backed by verified data.

⏩ Opportunity Identification: Discover emerging trends and untapped growth areas.

⏩ Risk Mitigation: Reduce uncertainties with thorough market evaluation.

⏩ Customer Insights: Understand consumer behavior, preferences, and buying patterns.

⏩ Strategic Planning Support: Align business strategies with market realities.

⏩ Time & Cost Efficiency: Save resources by leveraging ready-to-use research.

⏩ Customization & Expert Validation: Benefit from tailored insights and industry expert analysis.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

People Also Ask:

◆ How big is the Primary Sclerosing Cholangitis Market in 2025?
◆ What is the projected growth rate of the Primary Sclerosing Cholangitis Market through 2033?
◆ Who are the key players in the Primary Sclerosing Cholangitis Market?
◆ Which region is expected to dominate the industry during the forecast period?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.